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Edited by Masayuki MiyasakaAbstract KTS-disintegrins are a subfamily of short monomeric
disintegrins that are potent and selective inhibitors of a1b1
integrin. The amino acid sequence of the new KTS-disintegrin,
viperistatin, diﬀers from previously characterized obtustatin in
three residues at position 24 (within the integrin binding loop), 38
(hydrophobic core) and 40 (C-terminal region). Noteworthy,
viperistatin is about 25-fold more potent than obtustatin
inhibiting the binding of this integrin to collagen IV. Synthetic
peptides representing the full-length of integrin-binding loops of
these disintegrins showed that the Leu24/Arg substitution
appears to be partly responsible for the increased inhibitory
activity of viperistatin over obtustatin.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The collagen receptors create the separate subclass of inte-
grins that speciﬁcally interact with diﬀerent types of collagens
[1,2]. Among them, the most characterized are a1b1 and a2b1
integrins, which belong to I-domain containing integrins. I-
domain is a region within a-subunit containing approximately
200 amino acids, which has been identiﬁed as a speciﬁc inter-
active part responsible for the ligand binding [3,4]. Both inte-
grins are expressed on various cell types and play signiﬁcant
roles in the physiology of many organs. Recently, they have
become an interesting target for the development of new
cancer therapy, supported by inhibition of angiogenesis. a1b1
and a2b1 integrins are highly expressed on the microvascular
endothelial cells, and blocking of their adhesive properties by* Corresponding author. Fax: +1-215-204-6646.
E-mail address: cmarcink@temple.edu (C. Marcinkiewicz).
Abbreviations: BSA, bovine serum albumin; CMFDA, 5-chlorometh-
ylﬂuorescein diacetate; HPLC, high-performance liquid chromatogra-
phy; TFA, triﬂuoroacetic acid; MALDI-TOF, matrix-assisted
laser-desorption ionization time-of-ﬂight mass spectrometry; PBS,
phosphate-buﬀered saline
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doi:10.1016/j.febslet.2004.10.050monoclonal antibodies [5,6] or snake venom disintegrins [7]
signiﬁcantly reduced vascularization ratio and tumor growth
in animal models. Moreover, studies with a1 knockout mice
revealed major reduction of experimental tumor growth [8]
and similar studies with a2 knockout mice are on the way
[9,10]. Although a1b1 and a2b1 are structurally very homol-
ogous, their biological interactions appear to be signiﬁcantly
diﬀerent. a1b1 integrin is a selective receptor of basement
membrane collagen type IV, whereas a2b1 is highly speciﬁc for
ﬁbrillar collagens type I–III. Moreover, studies with genetic
substitution of cytoplasmic domains of a1 and a2 subunits in
transfected human mammary epithelial cells revealed involve-
ment of these two integrins in diﬀerent signal transduction
pathways [11]. a1b1 and a2b1 integrins showed also diﬀerent
patterns of interaction with snake venom-derived proteins.
a1b1 integrin speciﬁcally interacts with disintegrin obtustatin
[7,12], whereas a2b1 showed potent binding to C-lectin-type
proteins [13,14].
Snake venom disintegrins are a family of low molecular
weight proteins, showing anti-adhesive properties that are re-
lated to their speciﬁc interactions with certain integrins [15,16].
Structurally, they may occur as monomers or dimers and have
the molecular weight in the range from 4 to 15 kDa. Snake
venom disintegrins could be divided into three groups ac-
cording to their functional interaction with speciﬁc integrin
receptors. The ﬁrst group includes disintegrins that interact
with RGD-dependent integrins (aIIb3, av-integrins, and a5b1)
and is mainly represented by the disintegrins that contain
RGD sequence in their active site. The disintegrins containing
sequences related to RGD such as KGD [17], MGD [18] or
WGD [19] could be also assigned to this group. Second group
is created by heterodimeric disintegrins having MLD sequence
in the active site. They speciﬁcally block the function of certain
leukocyte integrins, including a4-integrins and a9b1 [20,21].
The last functional group of disintegrins includes selective in-
hibitors of a1b1 integrin. Currently, it is represented by the
only one disintegrin, obtustatin, that contains KTS sequence in
its active site [7,12]. Structurally, obtustatin belongs to short
monomeric disintegrins and recently its 3-D structure was
composed based on the NMR coordinates [22]. In the pre-
sented work, we report another KTS-containing disintegrin,
viperistatin, which also speciﬁcally interacts with a1b1
integrin.ation of European Biochemical Societies.
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2.1. Materials
Monoclonal antibody against 7S domain of collagen IV and puriﬁed
human a1b1 integrin were purchased from Chemicon (Temecula, CA).
Highly puriﬁed ﬁbrinogen was a gift from Dr. A. Budzynski (Temple
University, Philadelphia, PA); recombinant human VCAM-1/Ig was
received from Dr. R. Lobb (Biogen); human vitronectin was purchased
from Chemicon; human ﬁbronectin and laminin were purchased from
Sigma (St. Louis, MO).
Cell lines. K562 cells transfected with a1, a2 and a6 integrins were
provided by Dr. M. Hemler (Dana Farber Cancer Institute, Boston,
MA); JY cells expressing avb3 were a gift from Dr. Burakoﬀ (Dana
Farber Cancer Institute, Boston, MA); a9-transfected SW480 cells
were provided by Dr. Sheppard (University of California, San Fran-
cisco, CA); A5 cells, Chinese hamster ovary (CHO) cells transfected
with human aIIbb3 integrin [23] were kindly provided by Dr. M.
Ginsberg (Scripps Research Institute, La Jolla, CA); and K562 and
Jurkat cell lines were purchased from ATCC (Manassas, VA).
Snake venoms. Lyophilized Vipera lebetina obtusa and Echis soc-
hureki venoms were purchased commercially from Latoxan (France).
Venom of Vipera palestinae was collected from life specimens and kept
in captivity in the Zoology Department of Tel-Aviv University. The
snakes were manually milked during a period of one year and the
venom pooled from several snakes was lyophilized and kindly provided
to us by Prof. Avner Bdolah.
2.2. Puriﬁcation of collagen type IV
Collagen IV secreted by HT-1080 cells was puriﬁed from cell culture
media. HT-1080 cells were seeded into three separate intercommuni-
cating stacks of culture ﬂasks (6000 cm2 each; Cell FactoryTM, Nunc).
To harvest collagen IV, the cells were incubated in Dulbecco’s modi-
ﬁed Eagle’s medium supplemented with L-ascorbic acid phosphate
magnesium salt n-hydrate (Wako, Osaka, Japan) at a concentration of
40 lg/ml without fetal bovine serum for 24 h on each of six successive
days. The medium was ﬁltered through a 1.6 lm glass-ﬁber ﬁlter
(Millipore) and supplemented with the following reagents at the indi-
cated concentrations: 0.1 M Tris–HCl buﬀer, pH 7.4, 0.4 M NaCl, 25
mM EDTA, and 0.02% NaN3. High molecular weight proteins in the
medium were concentrated approximately 10-fold at 4 C. Proteins in
the concentrated media were precipitated overnight at 4 C with 175
mg/ml of ammonium sulfate and collected by centrifugation at
15 000 g for 1 h at 4 C. The pellets were resuspended overnight in
the storage buﬀer (0.1 M Tris–HCl buﬀer, pH 7.4, 0.4 M NaCl, 25 mM
EDTA and 0.02% NaN3) and insoluble material was removed by
centrifugation. The supernatant was dialyzed twice against 200 vol. of
buﬀer I (2 M urea, 0.2 M NaCl, 5 mM EDTA and 0.02% NaN3 in 0.1
M Tris–HCl buﬀer at pH 7.4), and the samples were chromatographed
on a DEAE-cellulose column (1.5 cm 10 cm) (DE 52, Whatman)
equilibrated and eluted with buﬀer I, and the ﬂow-through fraction
was collected. The sample was dialyzed against 200 vol. of buﬀer II (2
M urea, 2 mM EDTA, and 0.02% NaN3 in 0.075 M Tris–HCl buﬀer at
pH 7.8) and chromatographed on the second DEAE-cellulose column.
Collagen IV was collected in the ﬂow-through fraction and loaded
onto a column (1.5 cm 2 cm) of Q-Sepharose (Amersham) in the
same buﬀer. The puriﬁed collagen IV was dialyzed against storage
buﬀer and concentrated on a membrane ﬁlter (YM-100, Millipore)
under a pressure of 48 kPa.
2.3. Puriﬁcation of disintegrins
Obtustatin, viperistatin and echistatin were puriﬁed from the venoms
of Vipera lebetina obtusa, Vipera palestinae, and Echis suchoreki, re-
spectively, using the previously described two-steps reverse-phase high-
performance liquid chromatography (HPLC) [20,24]. Brieﬂy, the
venoms were dissolved in 0.1% triﬂuoroacetic acid (TFA) and sub-
jected to HPLC on a C18 (250 10 mm) reverse-phase column from
Vydac (Hesperia, CA). The linear acetonitrile gradient (0–80% in 0.1%
TFA over 45 min at a ﬂow rate 2 ml/min) was applied for elution of
venom fractions. Separation was monitored at 230 nm single wave-
length by UV detector (HPLC system from Waters). Obtustatin and
viperistatin were eluted with 48% and 40% of acetonitrile, respectively,
whereas echistatin was eluted with about 30% of acetonitrile. Fractions
containing the disintegrins were re-chromatographed using the same
column and developed with a ‘‘ﬂatter’’ acetonitrile gradient. The purity
of the disintegrins was assessed by SDS–PAGE and matrix-assistedlaser-desorption ionization time-of-ﬂight mass spectrometry (MALDI-
TOF-MS). Protein concentration was determined with the bicinchon-
inic acid protein quantiﬁcation kit (Pierce Co.) with bovine serum al-
bumin (BSA) as a standard.
2.4. Structural characterization of viperistatin
Puriﬁed viperistatin was reduced and alkylated as described previ-
ously [20]. S-Pyridylethylated (PE-) viperistatin was initially charac-
terized by N-terminal sequencing (using either an Applied Biosystem
Precise instrument), amino acid analysis (using a Beckman Gold
Amino Acid Analyzer after sample hydrolysis with 6 N HCl for 24 h at
110 C), and MALDI-TOF MS (as above). Quantitation of free cys-
teine residues and disulﬁde bonds was done as described [25]. The
primary structure of viperistatin was determined by N-terminal se-
quence analysis of the PE-protein and of HPLC-puriﬁed endopro-
teinase Lys-C-derived overlapping peptides [26].
2.5. Peptide synthesis
Peptides were prepared by solid phase synthesis on Wang resin and
ChemSpeed ASW 2000 synthesizer using Fmoc method and Benzo-
triazole-1-yl-oxy-tris (dimethylamino)-phosphonium hexaﬂuorophos-
phate as a coupling reagent. A pure peptide was obtained after
implementation of triple coupling for each cycle. The peptide was
cleaved from resin with 95% TFA and 1% triethylsilane and its
structure was characterized by ESI-MS. The peptides were dried by
lyophylization before application to adhesion assay.
2.6. Cell adhesion studies
Adhesion studies of cultured cells labeled with 5-chloromethylﬂuo-
rescein diacetate (CMFDA) were performed as described previously
[27].
2.7. ELISA assay
96-well plates (BD Falcon, Franklin Lakes, NJ) were coated with
puriﬁed a1b1 (5 lg/ml) overnight at 4 C in phosphate-buﬀered saline
(PBS). The wells were blocked with 5% non-fat milk (BioRad, Her-
cules, CA) in PBS/Tween 20 (PBST) buﬀer. Increasing concentrations
of disintegrins or synthetic peptides were added in Tris–HCl, pH 7.4,
buﬀer containing 150 mM NaCl, 1 mM MnCl2, and 1% BSA, and the
plate was incubated for 30 min at 37 C. After washing with the same
buﬀer, puriﬁed, human collagen IV was added at a concentration of 2
lg/ml. Incubation was continued for another 30 min at 37 C. The
bound collagen IV was detected by incubation with monoclonal anti-
body against 7S domain of collagen IV, following goat anti-human
IgG conjugated with alkaline phosphatase (Sigma) as described
previously [28].3. Results and discussion
The new KTS-containing disintegrin viperistatin was puri-
ﬁed from the venom of Vipera palestinae. Mass spectrometric
analysis of native and reduced S-pyridylethylated viperistatin
yielded isotope-averaged molecular masses of 4454.5 and
5303.2 Da, respectively. Incubation of viperistatin with 4-vi-
nylpyridine under denaturing, non-reducing conditions did not
change its molecular mass. Thus, the mass diﬀerence of 848.7
clearly indicated that viperistatin contained eight cysteine
residues engaged in the formation of 4 disulﬁde bonds. The
complete primary structure of viperistatin was established by
N-terminal sequencing of EP-protein (Fig. 1). Viperistatin
appeared to be highly homologous to obtustatin, another
KTS-containing disintegrin [12,13,22,29], diﬀering from it in
just three residues at positions 24, 38 and 40. Structurally,
KTS-disintegrins belong to a family of short monomeric dis-
integrins, which is mainly represented by RGD-containing
disintegrins such as echistatin, eristostatin, ocellatusin,
multisquamatin, pyramidin and leucogastin [25,30–32]. How-
ever, signiﬁcant diﬀerences have been observed in the
primary structure of short monomeric KTS-disintegrins and
Fig. 1. Comparison of the amino acid sequences of the short, monomeric disintegrins: viperistatin (V. palestinae, this work), obtustatin (V. lebetina
obtusa [12]), echistatin (E. sochureki [30]), eristostatin (E. macmahoni [31]) and ocellatusin (E. ocellatus [24]). Cysteines are underlined and the active
motifs are in italics. The double underlined are amino acid residues that are diﬀerent in viperistatin and obtustatin molecule. Asterisks below the
multiple sequence alignment indicate residues that are absolutely conserved among short monomeric disintegrins.
480 D.G. Kisiel et al. / FEBS Letters 577 (2004) 478–482RGD-disintegrins (Fig. 1). KTS-disintegrins contain lower
molecular weight resulting in shorter polypeptide chains (41
amino acids vs. 48–50 amino acids). The major diﬀerence is the
composition of integrin-binding loop. The active loop of KTS-
disintegrins is shorter by two amino acids and does not contain
any RGD related motif. This structural feature is strictly re-
ﬂected in activity. As shown in Table 1, KTS-disintegrins do
not express any anti-RGD-dependent integrins activity,
whereas RGD-containing echistatin potently inhibits aIIbb3,
avb3 and a5b1 integrins in adhesion assay. On the other hand,
obtustatin and viperistatin are potent inhibitors of a1b1 inte-
grin, and this kind of activity has not been found for any
RGD-disintegrins. Moreover, both KTS-disintegrins did not
show any activity against other integrins such as a4b1, a6b1,
and a9b1 (Table 1). Particularly interesting is the lack of in-
teraction with a2b1 integrin that is very homologous to a1b1
integrin, including sharing of similar endogenous ligands.
Previously, we identiﬁed the active site of obtustatin as a
KTS motif, using short peptide synthesis [7]. Viperistatin also
contains the same motif in the related site and shows also anti-
a1b1 integrin activity (Table 1, Fig. 2). However, viperistatin
appeared to be a much potent inhibitor of a1b1 integrin than
obtustatin. In the adhesion assay, viperistatin was 25-fold
more active in inhibition of a1K562 cell adhesion to both
collagen IV and collagen I. The same trend was observed when
the inhibitory activity of viperistatin and obtustatin was
compared in ELISA, where binding of collagen type IV to
immobilized puriﬁed a1b1 integrin was investigated (Fig. 2A).Table 1
Comparison of inhibitory eﬀects of obtustatin, viperistatin and echistatin on
Cell suspension Integrin Ligand IC5
Ob
a1K562 a1b1 Coll IV 2
a1K562 a1b1 Coll I 0.5
a2K562 a2b1 Coll I >1
a2K562 a2b1 Coll IV >1
a6K562 a6b1 LM >1
K562 a5b1 FN >5
Jurkat a4b1 VCAM-1 >1
SW480a9 a9b1 VCAM-1 >1
A5 aIIbb3 FG >1
JY avb3 VN >1
aThe data represent means of the results of three experiments. Coll, colla
molecule-1; FG, ﬁbrinogen and VN, vitronectin. a1, a2, a6K562, K562 ce
transfected with a9 integrin; A5 ¼ CHO cells transfected with aIIbb3 integThe fact that viperistatin and obtustatin diﬀer in just three
residues (L24/R within the integrin binding loop, L38/V in the
hydrophobic core, and P40/Q in the C-terminal region)
(Fig. 3), and viperistatin is a much potent inhibitor of a1b1
integrin than obtustatin, prompted us to investigate their
structure-function correlations using synthetic peptides. The
synthetic, linear peptides that respond to the amino acid se-
quences of entire integrin-binding loops for obtustatin
(CWKTSLTSHYC) and viperistatin (CWKTSRTSHYC) were
tested in adhesion and ELISA assays. KTSR-containing pep-
tide exposed IC50 ¼ 11:18 lM (Fig. 2B) and 105.25 lM
(Fig. 4) in ELISA and adhesion assays, respectively, whereas
KTSL-containing peptide showed IC50 ¼ 100:90 and 645.15
lM in the same assays, respectively. As a control, we used
synthetic peptide representing integrin binding-loop for
echistatin. This peptide (CKRARGDDMDDYC) was neither
active in ELISA nor in adhesion studies. Hence, replacement
of a leucine residue (obtustatin) with an arginine (viperistatin)
increases by 6- to 10-fold the inhibitory activity towards a1b1.
This conclusion is in line with previous studies showing the
functional relevance of amino acids ﬂanking both sides of the
primary integrin binding motifs. Presence of tryptophane
following RGD sequence in eristostatin potently increased the
activity of this disintegrin to inhibit aIIbb3 integrin if com-
pared with echistatin, containing aspartic acid in this site. On
the other hand, echistatin blocked the function of two other
RGD-dependent integrins, avb3 and a5b1, whereas eristosta-
tin showed negligible ability to interact with these integrins.various integrins in cell adhesion assaya
0 (nM)
tustatin Viperistatin Echistatin
0.08 >10 000
0.02 >10 000
0 000 >10 000 >10 000
0 000 >10 000 >10 000
0 000 >10,000 >10 000
000 >10 000 50
0 000 >10 000 >10 000
0 000 >10 000 >10 000
0 000 >10 000 50
0 000 >10 000 0.1
gen; LM, laminin; FN, ﬁbronectin; VCAM-1, vascular cell adhesion
lls transfected with a1, a2 or a6 integrins; SW480a9 ¼ SW480 cells
rin.
Fig. 2. Eﬀect of increasing concentrations of disintegrins (A) and synthetic peptides (B) on the binding of collagen IV to immobilized, puriﬁed a1b1
integrin in ELISA. On the panel (A), ﬁlled circles represent obtustatin; open circles viperistatin; ﬁlled triangles echistatin. On the panel (B), ﬁlled
circles represent obtustatin-derived peptide (CWKTSLTSHTC); open circles viperistatin-derived peptide (CWKTSRTSHTC); ﬁlled triangles
echistatin-derived peptide (CKRARGDDMDDYC). The data are represented by means calculated from three independent experiments.
Fig. 3. Stereo drawing of the NMR solution structure of obtustatin (1MPZ) [22] showing the location of the three residues (rendered in the ball-and-
stick representation) that diﬀerentiate this disintegrin from viperistatin: L24/R within the integrin binding loop, L38/V in the hydrophobic core, and
P40/Q in the C-terminal region (Fig. 1).
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tophane in echistatin molecule drastically decreased its activity
to interact with avb3 and a5b1 and increased potency to in-Fig. 4. Eﬀect of synthetic peptides, designed on the basis of active site
of obtustatin, viperistatin and echistatin in a1K562 cell adhesion assay.
The inhibitory eﬀects of peptides CWKTSLTSHTC (ﬁlled circles),
CWKTSRTSHTC (open circles) and CKRARGDDMDDYC (ﬁlled
triangles) were tested in an adhesion assay of CMFDA-labeled a1K562
cells to immobilized collagen IV. The error bars represent the standard
deviation in three independent experiments.hibit aIIbb3 [33]. Selectivity that is dependent from amino acid
composition of integrin-binding loop has also been observed
for MLD-containing disintegrins [21]. Threonine, which is
adjacent to MLD motif from N-terminus signiﬁcantly, in-
creased activity of VLO5 to block human a4b1 and a9b1 in-
tegrins in comparison with EC3 that contains alanine in this
place.
The partial relative enhancement of the inhibitory activity
of the KTSR-peptide suggests that the L38/V and P40/Q
substitutions of viperistatin may also contribute to the bio-
logical activity of this disintegrin. The L38/V substitution
within the hydrophobic core of viperistatin may not signif-
icantly alter the conformation of the disintegrin, and may
therefore represent a neutral mutation. On the other hand,
NMR studies of obtustatin [22,29] showed that the integrin
binding loop and the C-terminal tail are structurally linked
and display concerted motions in the 100–300 ps time-scale,
strongly indicating that these two functional regions may
form a conformational epitope (Fig. 3) engaged in extensive
interactions with the target integrin receptor. The P40/Q
substitution, along with the active site L24/R mutation, may
therefore create a distinct chemical environment responsible
for the increased inhibitory activity of viperistatin over
obtustatin.
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